Takashi Nishida
Saitama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Risk Factors for Pneumonitis in Patients with Unresectable Advanced Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Journal: Internal medicine (Tokyo, Japan)
Published: March 26, 2026
Predictive Factors for Invasive Mechanical Ventilation in Community-acquired Pneumonia.
Journal: Internal medicine (Tokyo, Japan)
Published: January 05, 2025
Serum TARC Level as a Predictive Marker of Severe Disease in COVID-19 during the Omicron Variant Period of the Pandemic.
Journal: Internal medicine (Tokyo, Japan)
Published: November 20, 2024
Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids.
Journal: Respiratory investigation
Published: June 12, 2024
A 74-Year-Old Woman With Dyspnea, Diffuse Bilateral Thickened Bronchovascular Bundle, Multiple Small Nodules, and a Thin-Walled Cavity.
Journal: CHEST pulmonary
Published: November 08, 2023
Live-Imaging Analysis of Target Vessels and Nitric Oxide Production Associated with Gosha-Jinki-Gan and Keishi-Bukuryo-Gan: Two Herbal Preparations with Clinically Proven Blood Flow-Improving Effects but with Different Traditional Clinical Indicative Patterns.
Journal: Evidence-based complementary and alternative medicine : eCAM
Published: November 14, 2021
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Journal: Nature
Published: October 26, 2021
Frequency and Significance of Coinfection in Patients with COVID-19 at Hospital Admission.
Journal: Internal medicine (Tokyo, Japan)
Published: September 21, 2021
Antigen avoidance and outcome of nonfibrotic and fibrotic hypersensitivity pneumonitis.
Journal: ERJ open research
Published: July 22, 2021
A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer.
Journal: Thoracic cancer
Published: January 05, 2021
Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Journal: Thoracic cancer
Published: August 12, 2020
Last Updated: 09/26/2026